PA6 price decline (11.1-11.30)

I. price trend:

According to the data of the business club’s bulk list, the domestic PA6 market weakened in November, with most brand quotations falling. The main offer price of traders for Zhongzhu 2.75-2.85 was about 12666.67 yuan / ton, down 6.17% from the beginning of the month.

II. Analysis of influencing factors:

The decline of caprolactam upstream of PA6 continued, and the price fell 5.1% in the month, and the decline gradually slowed down. The upstream pure benzene market continued to rise and boost, and it was difficult to find low-cost sources in the market, so the short-term market was strong. At present, domestic cyclohexanone manufacturers have made it clear that there are not many offers, and the delivery level of enterprises is around 7700-7800 yuan / ton. Most of them supply supporting downstream production demand, and the inventory level is low. The trading atmosphere of cyclohexanone market is fair, with a strong focus on high-end products. In addition, the slightly stronger raw materials give some support. The trend of caprolactam was weak, and the support for PA6 cost end was poor. The downstream purchasing enthusiasm is not good, the on-site trading is light, the factory traders operate cautiously, and the confidence is not strong. There are few large-scale purchases in the domestic market in the near future. At present, the market confidence is insufficient, the market still has resistance, and the bottom is not present. It is expected that the market price of caprolactam will be consolidated at a low level in the later period, and there is a risk of further decline; the upstream caprolactam will weaken, and the support for PA6 will be weakened. Affected by this negative, domestic PA6 spot prices mostly fell. In addition, at present, the supply of goods is relatively sufficient, and the downstream purchase and documentary are insufficient. At present, the domestic PA6 production and trade e-commerce companies offer low-level operation.

3. Future forecast:

In November, the domestic PA6 market weakened and spot prices fell, according to business analysts. Upstream caprolactam continued to decline, poor support for PA6 cost end. Downstream factories just need replenishment operation, the demand is flat and the list is light. It is expected that PA6 will continue to be weak in the near future.